Lincoln Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹491
- Today's High:
- ₹540.1
- Open Price:
- ₹530.15
- 52W Low:
- ₹273.7
- 52W High:
- ₹513
- Prev. Close:
- ₹533.8
- Volume:
- 55341
Company Statistics
- Market Cap.:
- ₹4.42 billion
- Book Value:
- 174.581
- Revenue TTM:
- ₹4.07 billion
- Operating Margin TTM:
- 16.32%
- Gross Profit TTM:
- ₹2.00 billion
- Profit Margin:
- 13.77%
- Return on Assets TTM:
- 9.56%
- Return on Equity TTM:
- 17.32%
Company Profile
Lincoln Pharmaceuticals Limited had its IPO on under the ticker symbol 531633.
The company operates in the Healthcare sector and Drug Manufacturers - Major industry. Lincoln Pharmaceuticals Limited has a staff strength of 0 employees.
Stock update
Shares of Lincoln Pharmaceuticals Limited opened at ₹530.15 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹491 - ₹540.1, and closed at ₹499.9.
This is a -6.35% slip from the previous day's closing price.
A total volume of 55,341 shares were traded at the close of the day’s session.
In the last one week, shares of Lincoln Pharmaceuticals Limited have slipped by -3.46%.
Lincoln Pharmaceuticals Limited's Key Ratios
Lincoln Pharmaceuticals Limited has a market cap of ₹4.42 billion, indicating a price to book ratio of 1.3122 and a price to sales ratio of 1.1532.
In the last 12-months Lincoln Pharmaceuticals Limited’s revenue was ₹4.07 billion with a gross profit of ₹2.00 billion and an EBITDA of ₹737.16 million. The EBITDA ratio measures Lincoln Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lincoln Pharmaceuticals Limited’s operating margin was 16.32% while its return on assets stood at 9.56% with a return of equity of 17.32%.
In Q3, Lincoln Pharmaceuticals Limited’s quarterly earnings growth was a positive 10.6% while revenue growth was a positive 11.9%.
Lincoln Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 8.1757
- PEG
Its diluted EPS in the last 12-months stands at ₹28.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lincoln Pharmaceuticals Limited’s profitability.
Lincoln Pharmaceuticals Limited stock is trading at a EV to sales ratio of 0.9325 and a EV to EBITDA ratio of 4.4709. Its price to sales ratio in the trailing 12-months stood at 1.1532.
Lincoln Pharmaceuticals Limited stock pays annual dividends of ₹3 per share, indicating a yield of 1.31% and a payout ratio of 5.35%.
Balance sheet and cash flow metrics
- Total Assets
- ₹5.87 billion
- Total Liabilities
- ₹722.84 million
- Operating Cash Flow
- ₹-366428000.00
- Capital Expenditure
- ₹142.82 million
- Dividend Payout Ratio
- 5.35%
Lincoln Pharmaceuticals Limited ended 2024 with ₹5.87 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹5.87 billion while shareholder equity stood at ₹5.02 billion.
Lincoln Pharmaceuticals Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹722.84 million in other current liabilities, 200297000.00 in common stock, ₹4.82 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹50.52 million and cash and short-term investments were ₹1.26 billion. The company’s total short-term debt was ₹19,972,000 while long-term debt stood at ₹0.
Lincoln Pharmaceuticals Limited’s total current assets stands at ₹3.67 billion while long-term investments were ₹0 and short-term investments were ₹920.04 million. Its net receivables were ₹1.36 billion compared to accounts payable of ₹0 and inventory worth ₹700.28 million.
In 2024, Lincoln Pharmaceuticals Limited's operating cash flow was ₹-366428000.00 while its capital expenditure stood at ₹142.82 million.
Comparatively, Lincoln Pharmaceuticals Limited paid ₹0.05 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹499.9
- 52-Week High
- ₹513
- 52-Week Low
- ₹273.7
- Analyst Target Price
- ₹
Lincoln Pharmaceuticals Limited stock is currently trading at ₹499.9 per share. It touched a 52-week high of ₹513 and a 52-week low of ₹513. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹453.72 and 200-day moving average was ₹384.97 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5919.4% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Lincoln Pharmaceuticals Limited
Similar Industry Stocks (Drug Manufacturers - Major)
Most Active
Top Gainers
Top Losers
About
Lincoln Pharmaceuticals Limited manufactures and sells pharmaceutical products in India and internationally. It offers products in the areas of anti-infective, respiratory system, gynecology, cardio and CNS, anti-bacterial, ant-diabetic, anti-malaria, and others areas. The company also trades in pharmaceutical products. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.